180 active trials 102 recruiting 22 Phase 3 115 sponsors 34 changes in 30 days
| Early Phase 1 | 1 | |
| Phase 1 | 17 | |
| Phase 1/2 | 20 | |
| Phase 2 | 82 | |
| Phase 2/3 | 6 | |
| Phase 3 | 16 | |
| Phase 4 | 2 |
| NCT ID | Title | Sponsor | Status | Updated |
|---|---|---|---|---|
| Phase 4 | ||||
| NCT07619235 | A Single-arm, Multicenter Clinical Study of Iparomlimab and Toripalimab in Combination… | Xianglin Yuan | Not Yet Recruiting | 2026-06-01 |
| NCT06818773 | Inetetamab Plus Chemotherapy ± PD-1/PD-L1 in HER2+ Advanced Biliary Cancer | Eastern Hepatobiliary Surgery Hospital | Not Yet Recruiting | 2025-02-10 |
| Phase 3 | ||||
| NCT07221253 | A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of… | AstraZeneca | Recruiting | 2026-08-21 |
| NCT06467357 | Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary… | AstraZeneca | Recruiting | 2026-08-19 |
| NCT06622057 | D07001 Softgel-Capsules and Capecitabine Combination Therapy in Patients With Advanced… | InnoPharmax Inc. | Recruiting | 2026-07-30 |
| NCT07582315 | A Study Comparing BL-B01D1 With Treatment of Physician's Choice in Patients With Locally… | Sichuan Baili Pharmaceutical Co., Ltd. | Recruiting | 2026-07-24 |
| NCT07606599 | A Study of BL-M07D1 Versus Physician's Choice of Chemotherapy in Patients With… | Sichuan Baili Pharmaceutical Co., Ltd. | Recruiting | 2026-07-24 |
| NCT07710885 | Futibatinib (TAS-120) in Patients With Advanced Biliary Tract Cancer | Taiho Pharmaceutical Co., Ltd. | Recruiting | 2026-07-17 |
| NCT06282575 | Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care… | Jazz Pharmaceuticals | Recruiting | 2026-07-14 |
| NCT07265674 | A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B)… | J-Pharma Co., Ltd. | Recruiting | 2026-07-01 |
| NCT07229625 | A Phase III Study of SHR-8068 in Combination With Adebrelimab and Platinum-Containing… | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Recruiting | 2026-01-28 |
| NCT07062263 | Trastuzumab Plus Chemotherapy vs Chemotherapy Alone in First-line HER2 Positive Advanced… | Tata Memorial Centre | Recruiting | 2025-07-14 |
| NCT03875235 | Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line… | AstraZeneca | Active, Not Recruiting | 2026-08-26 |
| NCT07745296 | Investigating Precision Medicine in the Adjuvant Setting in Biliary Tract Cancer | UNICANCER | Not Yet Recruiting | 2026-08-04 |
| NCT05771480 | Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary… | AstraZeneca | Active, Not Recruiting | 2026-07-29 |
| NCT06109779 | Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection… | AstraZeneca | Active, Not Recruiting | 2026-07-10 |
| NCT06591520 | AK112 Combined With Chemotherapy Versus Durvalumab Combined With Chemotherapy in Advanced… | Akeso | Active, Not Recruiting | 2026-01-21 |
| NCT02170090 | Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Standard of Care After… | Universitätsklinikum Hamburg-Eppendorf | Active, Not Recruiting | 2025-03-30 |
| Phase 2/3 | ||||
| NCT05065957 | Study of Combination Therapy of D07001-Softgel Capsules and Xeloda/TS-1 in Subjects With… | InnoPharmax Inc. | Recruiting | 2025-04-30 |
| NCT06037980 | CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative Chemotherapy Versus… | Gruppo Oncologico del Nord-Ovest | Recruiting | 2025-02-17 |
| NCT07765433 | Testing the Addition of Ivonescimab Combined With Standard Chemotherapy Compared to the… | ECOG-ACRIN Cancer Research Group | Not Yet Recruiting | 2026-08-14 |
| NCT05506943 | A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable… | Compass Therapeutics | Active, Not Recruiting | 2026-05-07 |
| NCT07437287 | Testing Mitazalimab in Combination With Standard Chemotherapy in Immunotherapy Resistant… | UNICANCER | Not Yet Recruiting | 2026-02-27 |
| NCT06662877 | Anlotinib Plus Nab-Paclitaxels and S-1 for Patients with Advanced Biliary Tract Cancer As… | Sun Yat-sen University | Not Yet Recruiting | 2024-10-29 |
| Phase 2 | ||||
| NCT07786766 | Pemigatinib Plus PD-1 Inhibitor With or Without Chemotherapy in FGFR2… | Haitao Zhao, MD | Recruiting | 2026-08-26 |
AstraZeneca (9) · Peking Union Medical College Hospital (8) · Tianjin Medical University Cancer Institute and Hospital (6) · Shanghai Zhongshan Hospital (5) · Tongji Hospital (5) · CHA University (4) · Suzhou Suncadia Biopharmaceuticals Co., Ltd. (4) · Asan Medical Center (3) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (3) · Eastern Hepatobiliary Surgery Hospital (3)